#VisualAbstract: Belantamab Mafodotin in Combination with Standard-Care Therapies Improved Progression-Free Survival in Patients with Multiple Myeloma Compared to Standard-Therapy Alone
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may...